{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:33:44Z","timestamp":1768736024015,"version":"3.49.0"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,8,26]],"date-time":"2013-08-26T00:00:00Z","timestamp":1377475200000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Birth Defects Research Pt B"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Valproic acid (VPA), widely used to treat epilepsy, bipolar disorders, and migraine prophylaxis, is known to cause neural tube and skeletal defects in humans and animals. Aminobenzensulfonamide derivatives of VPA with branched aliphatic carboxylic acids, namely 2\u2010methyl\u2010<jats:italic>N<\/jats:italic>\u2010(4\u2010sulfamoyl\u2010phenyl)\u2010pentanamide (MSP), 2\u2010ethyl\u2010N\u2010(4\u2010sulfamoyl\u2010phenyl)\u2010butyramide (ESB), 2\u2010ethyl\u20104\u2010methyl\u2010<jats:italic>N<\/jats:italic>\u2010(4\u2010sulfamoyl\u2010phenyl)\u2010pentanamide (EMSP), and 2\u2010ethyl\u2010<jats:italic>N<\/jats:italic>\u2010(4\u2010sulfamoyl\u2010benzyl)\u2010butyramide (ESBB), have shown more potent anticonvulsant activity than VPA in preclinical testing. Here, we investigated the teratogenic effects of these analogous compounds of VPA in NMRI mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Pregnant NMRI mice were given a single subcutaneous injection of either VPA at 1.8 or 3.6 mmol\/kg, or MSP, ESB, EMSP, or ESBB at 1.8, 3.6, or 4.8 mmol\/kg on gestation day (GD) 8. Cesarean section was performed on GD 18, and the live fetuses were examined for external and skeletal malformations.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Compared with VPA, which induced neural tube defects (NTDs) in fetuses at 1.8 and 3.6 mmol\/kg, the analog derivatives induced no NTDs at dose levels up to 4.8 mmol\/kg (except for a single case of exencephaly at 4.8 mmol\/kg MSP). Skeletal examination showed several abnormalities mainly at the axial skeletal level with VPA at 1.8 mmol\/kg. Fused vertebrae and\/or fused ribs were also observed with MSP, ESB, EMSP, and ESBB, they were less severe and seen at a lower incidence that those induced by VPA at the same dose level.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>In addition to exerting more potent preclinical antiepileptic activity, teratology comparison indicates that aminobenzensulfonamide analogs are generally more weakly teratogenic than VPA.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bdrb.21068","type":"journal-article","created":{"date-parts":[[2013,8,26]],"date-time":"2013-08-26T14:44:43Z","timestamp":1377528283000},"page":"318-327","source":"Crossref","is-referenced-by-count":1,"title":["Teratology Study of Amide Derivatives of Branched Aliphatic Carboxylic Acids with 4\u2010Aminobenzensulfonamide in NMRI Mice"],"prefix":"10.1002","volume":"98","author":[{"given":"Yuko","family":"Onishi","sequence":"first","affiliation":[{"name":"Drug Safety Research Laboratories Astellas Pharma Inc  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Okada","sequence":"additional","affiliation":[{"name":"Drug Safety Research Laboratories Astellas Pharma Inc  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Noyori","sequence":"additional","affiliation":[{"name":"Drug Safety Research Laboratories Astellas Pharma Inc  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Okamura","sequence":"additional","affiliation":[{"name":"Drug Safety Research Laboratories Astellas Pharma Inc  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naama","family":"Hen","sequence":"additional","affiliation":[{"name":"Institute of Drug Research School of Pharmacy Faculty of Medicine The Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Yagen","sequence":"additional","affiliation":[{"name":"Institute of Drug Research School of Pharmacy Faculty of Medicine The Hebrew University of Jerusalem  Jerusalem Israel"},{"name":"David R. Bloom Center for Pharmacy The Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[{"name":"Institute of Drug Research School of Pharmacy Faculty of Medicine The Hebrew University of Jerusalem  Jerusalem Israel"},{"name":"David R. Bloom Center for Pharmacy The Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Drug Safety Research Laboratories Astellas Pharma Inc  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.007"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.11.006"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0272-0590(88)90112-1"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00462-2"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx950216s"},{"key":"e_1_2_7_7_1","first-page":"808","volume-title":"Antiepileptic Drugs","author":"Bourgeois BFD.","year":"2002"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/479364"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10937400490512447"},{"issue":"1","key":"e_1_2_7_10_1","first-page":"97","article-title":"Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)\u2010C cells by valproic acid: enhancement by combination with interferon\u2010alpha","volume":"20","author":"Cinatl J","year":"2002","journal-title":"Int J Oncol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206814"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420440604"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0890-6238(91)90091-S"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420450208"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420380403"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0890-6238(91)90090-3"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100170w"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420380405"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200304000-00014"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/tcm.1770010405"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/10520298109067325"},{"key":"e_1_2_7_22_1","first-page":"780","volume-title":"Antiepileptic drugs","author":"Levy RH","year":"2002"},{"key":"e_1_2_7_23_1","first-page":"767","volume-title":"Antiepileptic Drugs","author":"Loscher W.","year":"2002"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2010.00203.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6866(1996)16:2<97::AID-TCM4>3.0.CO;2-A"},{"key":"e_1_2_7_26_1","first-page":"99","article-title":"Stage\u2010dependent skeletal malformations induced by valproic acid in rat","volume":"42","author":"Menegola E","year":"1998","journal-title":"Int J Dev Biol"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0890-6238(02)00056-4"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1984.tb05637.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1741-4520.1997.tb00547.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(85)90081-X"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420330105"},{"key":"e_1_2_7_32_1","first-page":"52","article-title":"Valproic acid teratogenesis","volume":"1","author":"Nau H","year":"1987","journal-title":"ISI Atlas Sci Pharmacol"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1991.tb01303.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01962697"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.10057"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20078"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.20490"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20209"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-0590(83)80067-0"},{"key":"e_1_2_7_40_1","first-page":"81","article-title":"The human vertebral column at the end of the embryonic period proper. 3. The thoracicolumbar region","volume":"168","author":"O'Rahilly R","year":"1990","journal-title":"J Anat"},{"key":"e_1_2_7_41_1","first-page":"192","article-title":"Exencephaly and axial skeletal malformations induced by maternal administration of sodium valproate in the MF1 mouse","volume":"14","author":"Padmanabhan R","year":"1994","journal-title":"J Craniofac Genet Dev Biol"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0890-6238(96)00081-0"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420340305"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2008.03.051"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20134"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420350205"},{"key":"e_1_2_7_47_1","first-page":"36","volume-title":"Antiepileptic Drugs","author":"White HS","year":"2002"}],"container-title":["Birth Defects Research Part B: Developmental and Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdrb.21068","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdrb.21068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T23:35:17Z","timestamp":1696635317000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdrb.21068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1002\/bdrb.21068"],"URL":"https:\/\/doi.org\/10.1002\/bdrb.21068","archive":["Portico"],"relation":{},"ISSN":["1542-9733","1542-9741"],"issn-type":[{"value":"1542-9733","type":"print"},{"value":"1542-9741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}